The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.

Up to 76% of patients with Alzheimer’s disease experience agitation, including pacing, restlessness and verbal or physical aggression.

A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.

GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% reduction in dementia risk.

More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with UNLV.

A blood test for Alzheimer’s Disease a game-changer for patients and their families.

As current drugs fall short, companies are exploring new targets to treat the neurodegenerative disease

For decades, diagnosing Alzheimer’s disease (AD) has required access to specialist memory clinics, neuroimaging or invasive cerebrospinal fluid (CSF) testing. That paradigm is starting to shift. In 2025, the US Food and Drug Administration (FDA) cleared the first blood-based biomarker tests intended to aid the assessment of AD.